President Donald Trump threw shade at his rival Rep. Nancy Pelosi when asked if members of Congress should be banned from ...

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced that 18 abstracts, including one oral presentation, have ...

Tempus AI TEM has skyrocketed 21% in the last three days, fueled by news of a $200 million partnership with AstraZeneca AZN ...

Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $63.78, ...

Tempus AI (TEM) has seen a significant surge on Wednesday, with its stock climbing 14.62% in just one day. The significant boost in TEM stock ...

With the stock market in rally mode, there are more pockets of strength than there have been in a while. Among the winners ...

Amid a bullish backdrop for the broader market, Tempus AI (NASDAQ: TEM) stock is posting big gains Wednesday. The company's ...

Tempus AI Inc (NASDAQ:TEM) shares are surging Wednesday after the company announced a multi-year collaboration with ...

The share price of health technology company Tempus AI (NASDAQ: TEM) has soared by double digits, fueled by positive investor ...

Tempus stands to earn $200 million in data licensing and model development fees from the collaborations, the release said.

Tempus AI shares were 14% higher, at $49.35, after the company said it has entered into multi-year strategic collaborations with AstraZeneca and Pathos AI.

Shares of Tempus AI ( TEM 17.39%) were skyrocketing 16.5% higher as of 10:39 a.m. ET on Wednesday. The big gain came after ...